The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories has recalled one lot of Ziprasidone Hydrochloride Capsules (20 mg) because the cartons may actually contain Dronabinol Capsules (2.5 mg) due to a labeling mix-up. This recall affects unit dose cartons containing 40 capsules. No incidents or injuries have been reported to date regarding this mix-up.
Taking the wrong medication can lead to serious adverse health effects. Ziprasidone is used to treat schizophrenia and bipolar disorder, while Dronabinol is a synthetic cannabinoid; taking the incorrect drug may lead to ineffective treatment of the primary condition or unexpected side effects and drug interactions.
You have 2 options:
Cartons labeled as Ziprasidone may contain Dronabinol Capsules USP, 2.5 mg.
Image 1, Carton Label for Dronabinol Capsules, USP, 2.5 mg
Image 2, Carton Label for Ziprasidone Hydrochloride Capsules, USP, 20 mg
Image 3, Blister Packaging Label for Dronabinol Capsules, USP, 2.5 mg
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · FDA Press Release · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.